Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
We break down expense ratios across popular index funds and show how choosing the lowest-cost options can improve long-term retirement outcomes.
28,023 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
AMD sits near a pivotal $420 level as first-quarter results underscore strong data-center demand and a bold AI-driven...
Meta Platforms has hovered around a pivotal level. This guide weighs the pros, cons, and real-world steps to decide i...
Insider transactions can reveal confidence or caution. This guide digs into ultra clean insider sells, what they sign...
Oil markets are dictating Bitcoin moves as geopolitical risk deepens, outpacing CPI and ETF factors. Traders say the ...
A federal judge pressed the government over its bid to block Anthropic’s AI from top-secret systems. The hearing unde...
Truth Social’s spot Bitcoin ETF has withdrawn its S-1 filing, signaling tougher market conditions for plain-vanilla c...
Analysts just boosted Crocs stock after recent upgrade rumors and data. This guide breaks down why the upgrade happen...
U.S. households are trimming credit-card balances as total debt hovers near $1.25 trillion, signaling a shift in cons...
Joby Aviation has faced a rough start to 2026 after a big rally in 2025. This guide explains whether the stock is rig...
SanDisk announced a $1 billion strategic equity investment in Nanya Technology, prompting a roughly 6% share decline ...
Bitcoin, Ethereum, and XRP led a weekend comeback, lifting the total crypto market cap and centering attention on a p...